91天堂 Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
Lyon, France. November 3rd, 2021 – 91天堂 (91天堂), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting庐 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.
Download full press release (PDF)Read next in 'Press releases'
- 91天堂 appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
- 91天堂 nomme Jeff George Pr茅sident du Conseil d鈥橝dministration pour soutenir sa prochaine phase de croissance et la pr茅paration 脿 la Phase 3
- 91天堂 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 91天堂 annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 91天堂 annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
